Loestrin: profile and news

FDA Approves New Oral Contraceptive Loestrin 24 Fe (norethindrone ... Feb 20, 2006
NJ -- February 20, 2006 -- Warner Chilcott announced that the US Food and Drug Administration (FDA) has approved its 24-day oral contraceptive, Loestrin(R) 24 ... - DG News

New Oral Contraceptive, Loestrin(R) 24 Fe, Approved By FDA Feb 20, 2006
Warner Chilcott announced today that the US Food and Drug Administration (FDA) has approved its 24-day oral contraceptive, Loestrin(R) 24 Fe (norethindrone ... - Medical News Today (press release),

FDA OKs Warner Chilcott's contraceptive Feb 20, 2006
ROCKAWAY, NJ, Feb. 20 (UPI) -- Warner Chilcott said late Friday its oral contraceptive Loestrin 24 FE has been approved for market. ... - United Press International

New Oral Contraceptive Approved by FDA Feb 17, 2006
17 /PRNewswire/ -- Warner Chilcott announced today that the US Food and Drug Administration (FDA) has approved its 24-day oral contraceptive, Loestrin® 24 Fe ... - Yahoo! News (press release)

Warner Chilcott Reports Results for the Quarter and Nine Months ... Nov 11, 2005
Adjusted EBITDA for the nine months ended September 30, 2004 excludes profits associated with sales of certain divested LOESTRIN(R) branded oral contraceptive ... - PR Newswire (press release),

PROPOSED ACQUISITION OF WOMEN’S HEALTHCARE PRODUCTS PORTFOLIO ... Oct 3, 2005
...of Galen's acquisition of the women’s healthcare pharmaceutical brands comprising, in addition to femhrt®, the oral contraceptives, Estrostep® and Loestrin ... - Biotechnology Investment Today (Press Release),

Warner Chilcott Reports Results for the Quarter and Six Months ... Aug 15, 2005
Adjusted EBITDA for the six months ended June 30, 2004 excludes profits associated with sales of certain divested LOESTRIN(R) branded oral contraceptive ... - Black Enterprise,

Concentric Wins Agency of Record Assignment for Warner Chilcott's ... Jul 12, 2005
YORK- July 12, 2005 - Concentric healthcare advertising was selected to develop the launch campaign for Warner Chilcott's new oral contraceptive, Loestrin 24. ... - PharmaLive.com (press release) <**results**>

Warner Chilcott Reports Results for The Quarter Ended March 31 ... Jun 27, 2005
Adjusted EBITDA for the prior year quarter includes the elimination of profits associated with sales of certain divested LOESTRIN(R) branded oral contraceptive ... - Black Enterprise,

Barr Reports Third Quarter Fiscal 2005 Earnings of $0.58 Per Share May 5, 2005
...which was launched in November 2003, along with contributions from products acquired during the previous twelve months, including Loestrin®/Loestrin® Fe oral ... - Yahoo News

Barr Reports Third Quarter Fiscal 2005 Earnings of $0.58 Per Share May 5, 2005
R), which was launched in November 2003, along with contributions from products acquired during the previous twelve months, including Loestrin(R)/Loestrin(R ... - PharmaLive.com,

Paladin reports 2004 fourth quarter and year end results Feb 17, 2005
Canadian marketing and promotion agreement with Duramed Pharmaceuticals, Inc., a wholly-owned subsidiary of Barr Pharmaceuticals, Inc., for Loestrin(R) and ... - Canada NewsWire (press release),

Other information

Indication
For treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.

Pharmacology
Ethinyl estradiol is a synthetic derivative of the natural estrogen estradiol. It is one of two estrogens currently used in oral contraceptive pills. The other, mestranol, is converted to ethinyl estradiol before it is biologically active. Ethinyl estradiol and norethindrone are used together as an oral contraceptive agent.

Mechanism Of Action
Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).

Drug Category
Estrogens; ATC:G03CA01

Brand Names/Synonyms
17?-Ethynylestradiol; 17alpha-Ethinylestradiol; 17alpha-Ethynylestradiol; 17alpha-Ethynyloestradiol; Aethinyloestradiolum; Aethinyoestradiol [German]; Alesse; Alora; Amenoron; Amenorone; Anovlar; BRN 2419975; Binovum; Brevicon; Brevinor; CCRIS 286; CHEMBANK1139; Climara; Conceplan; Cyclosa; Demulen; Desogen; Dicromil; Diognat-E; Diogyn E; Diogyn-E; Diprol; Dyloform; EE; EE2; EO; ETHINYLESTRADIOL; Ertonyl; Esclim; Esteed; Estigyn; Estinyl; Eston-E; Estopherol; Estoral; Estoral {[Orion]}; Estorals; Estrace; Estraderm; Estradiol; Estring; Estrogel; Estrogen; Ethidol; Ethinoral; Ethinyl Estradiol; Ethinyl-Oestranol; Ethinylestradiolum [Inn-Latin]; Ethinylestriol; Ethinyloestradiol; Ethy 11; Ethynylestradiol; Ethynyloestradiol; Eticyclin; Eticyclol; Eticylol; Etinestrol; Etinestryl; Etinilestradiol [Inn-Spanish]; Etinilestradiolo [Dcit]; Etinoestryl; Etistradiol; Etivex; Feminone; Fempatch; Follicoral; Genora; Ginestrene; Gynodiol; Gynolett; HSDB 3587; Halodrin; Inestra; Innofem; Jenest; Kolpolyn; Levlen; Linoral; Lo/Ovral; Loestrin; Logynon; Lynoral; Marvelon; Menolyn; Menostar; Mercilon; Microfollin; Microgynon; Mircette; Modicon; NEE; NSC-10973; Necon; Nelova; Neo-Estrone; Neocon; Nogest-S; Norcept; Nordette; Norethin 1/35 E; Norimin; Norinyl; Norlestrin; Novestrol; Oradiol; Orestralyn; Orestrayln; Ortho Tri-Cyclen; Ortho-Cept; Ortho-Cyclen; Ortho-Novum; Ovcon; Ovex; Oviol; Ovral; Ovran; Ovranette; Ovysmen; Palonyl; Perovex; Primogyn; Primogyn C; Primogyn M; Progynon C; Progynon M; Prosexol; Spanestrin; Stediril; Synphase; Tetragynon; Thiuram E; Thiuranide; Tri-Levlen; Tri-Norinyl; Trinordiol; Trinovum; Triphasil; Vagifem; Varnoline; Vivelle; Ylestrol

Dosage Forms
DISC (SUSTAINED-RELEASE); GEL; IMPLANT; LIQUID; PATCH; RING (SLOW-RELEASE); SOLUTION; TABLET

Absorption
Rapid and complete absorption follows oral intake of ethinyl estradiol (bioavailability 43%).

Interactions
Drug Interactions for Ethinyl Estradiol:

Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives. The following similar changes may be expected with larger doses of estrogen:

Increased sulfobromophthalein retention; increased prothrombin and factors VII, VIII, IX, and X; decreased antithrombin 3; increased norepinephrine-induced platel et aggregation; increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by PBI, T₄ by column, or T₄ by radioimmunoassay. Free T₃ resin uptake is decreased, reflecting the elevated TBG; free T₄ concentration is unaltered: impaired glucose tolerance; decreased pregnanediol excretion; reduced response to metyrapone test; reduced serum folate concentration; increased serum triglyceride and phospholipid concentration.

Chemical IUPAC Name
17-ethynyl-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol

Chemical Formula
C20H24O2

Half Life
36 +/- 13 hours

Drug Type
Approved Drug

# Accession No
APRD00691

CAS Registry Number
57-63-6